ArticleMedical oncology (Northwood, London, England)2022

Chk1/2 inhibitor AZD7762 enhances the susceptibility of IDH-mutant brain cancer cells to temozolomide.

Erkin Ozgiray et al.PubMed ↗Publisher ↗

No numbers read from the abstract.